DIVISLAB

Divi’s Laboratories – Latest Updates

1. Q1 FY26 Results (June 2025 Quarter) Net Profit rose 27% YoY to around ₹545 crore. Revenue grew 14% YoY but fell short of analyst expectations. Stock price dropped ~3% post-results due to pricing pressure in U.S. generics. Management highlighted increased competition in global markets as a short-term challenge. 2. Q4 FY25 Results (March 2025 Quarter) Profit After Tax jumped 26% YoY to about ₹667 crore. Revenue increased 12% YoY to approximately ₹2,536 crore. Shares rallied around 3% after results, supported by strong earnings growth. Analysts remained mixed: some retained Buy ratings, while others stayed Neutral citing high valuations. 3. Dividend Update The company went ex-dividend in July 2025. Eligible shareholders received the declared dividend. 4. Strategic Positioning Among the top global API manufacturers with exports to over 100 countries. Strong expertise in custom synthesis, generic APIs, intermediates, and nutraceuticals. Multiple large-scale manufacturing facilities and R&D centers across India. 5. Key Themes for Investors Strengths: Strong earnings growth, global leadership in APIs, solid balance sheet. Risks: Pricing pressure in U.S. markets, intense generics competition, margin sensitivity. Outlook: Long-term fundamentals remain strong, though near-term volatility is likely due to global pricing trends.